1. A method of treating an inflammatory disease or disorder in a subject in which a PKC inhibitor is administered to the subject and thereby treating the inflammatory disease or disorder in the subject. The method of claim 1, wherein the inhibitor is a polypeptide. The method of claim 2, wherein the polypeptide comprises an N-terminal modification, a C-terminal modification, or a combination thereof. The method of claim 2, wherein the polypeptide is N-acylated. The method of claim 2, wherein the polypeptide is N-myristoylated or N-palmitoylated. The method of claim 2, wherein the polypeptide is administered parenterally. The method of claim 2, wherein the polypeptide is administered subcutaneously or intravenously. The method of claim 2, wherein the polypeptide is administered topically, orally, through the mucosa, rectally, pulmonary, nasal, or through the ear. The method of claim 2, wherein the polypeptide is administered at a dose of from about 0.1 to about 10,000 μg / kg. The method of claim 2, wherein the polypeptide is administered at a dose of from about 0.1 to about 1000 μg / kg. The method of claim 2, wherein the polypeptide is administered at a dose of from about 1.0 to about 50 μg / kg. The method of claim 2, wherein the polypeptide is administered daily, weekly, every two weeks, or monthly. The method of claim 1, wherein the inflammatory disease or disorder is selected from the group comprising psoriasis, multiple sclerosis, rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto thyroiditis, myasthenia gravis, type 1 and type 2 diabetes, asthma, inflammatory lung damage, inflammatory liver damage inflammatory glomerular damage, atopic dermatitis, allergic contact dermatitis, contact dermatitis, seborrheic dermatitis, Sjogren's syndrome, keratoconjunctivitis, uveitis, inflammatory disease1. Способ лечения воспалительного заболевания или расстройства у субъекта, при котором субъекту вводят ингибитор РКС и, таким образом, лечат воспал
